IRIS
DELLA PORTA, MATTEO GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.806
AS - Asia 3.822
EU - Europa 2.801
SA - Sud America 475
AF - Africa 117
Continente sconosciuto - Info sul continente non disponibili 14
OC - Oceania 10
Totale 12.045
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.700
CN - Cina 2.005
SG - Singapore 736
IE - Irlanda 596
HK - Hong Kong 424
UA - Ucraina 415
FI - Finlandia 385
BR - Brasile 382
VN - Vietnam 331
DE - Germania 288
RU - Federazione Russa 259
IT - Italia 227
FR - Francia 172
SE - Svezia 169
GB - Regno Unito 163
IN - India 67
CA - Canada 54
BD - Bangladesh 36
MX - Messico 36
ZA - Sudafrica 35
AR - Argentina 32
JP - Giappone 29
IQ - Iraq 26
TR - Turchia 25
PL - Polonia 21
NL - Olanda 20
CO - Colombia 18
PK - Pakistan 17
BE - Belgio 16
EC - Ecuador 16
ID - Indonesia 15
SA - Arabia Saudita 15
AT - Austria 14
KE - Kenya 13
UZ - Uzbekistan 13
ES - Italia 12
TN - Tunisia 12
CZ - Repubblica Ceca 11
EU - Europa 10
MU - Mauritius 10
AU - Australia 9
MA - Marocco 9
PH - Filippine 9
NP - Nepal 8
AZ - Azerbaigian 7
JO - Giordania 7
KZ - Kazakistan 7
BO - Bolivia 6
CL - Cile 6
EG - Egitto 6
ET - Etiopia 6
IL - Israele 6
LT - Lituania 6
MY - Malesia 6
RO - Romania 6
PY - Paraguay 5
AE - Emirati Arabi Uniti 4
CH - Svizzera 4
NG - Nigeria 4
OM - Oman 4
PA - Panama 4
UY - Uruguay 4
AM - Armenia 3
CR - Costa Rica 3
DZ - Algeria 3
GE - Georgia 3
HU - Ungheria 3
LA - Repubblica Popolare Democratica del Laos 3
LB - Libano 3
PE - Perù 3
PT - Portogallo 3
SK - Slovacchia (Repubblica Slovacca) 3
VE - Venezuela 3
XK - ???statistics.table.value.countryCode.XK??? 3
AO - Angola 2
BW - Botswana 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
GH - Ghana 2
GR - Grecia 2
JM - Giamaica 2
KR - Corea 2
KW - Kuwait 2
MN - Mongolia 2
NI - Nicaragua 2
SN - Senegal 2
BF - Burkina Faso 1
BG - Bulgaria 1
CG - Congo 1
CI - Costa d'Avorio 1
CM - Camerun 1
CU - Cuba 1
CV - Capo Verde 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
GA - Gabon 1
GN - Guinea 1
GT - Guatemala 1
HN - Honduras 1
KG - Kirghizistan 1
Totale 12.032
Salva come PNG Salva come JPEG
Città #
Chandler 692
Dublin 596
San Jose 593
Jacksonville 522
Nanjing 459
Hong Kong 419
Ashburn 376
Singapore 357
Beijing 286
Dallas 234
Boardman 222
Nanchang 176
Princeton 136
Lawrence 131
Changsha 129
Wilmington 128
Hebei 116
Lauterbourg 116
Medford 109
Shenyang 107
Helsinki 102
Ho Chi Minh City 102
Los Angeles 102
Jiaxing 92
New York 92
Hanoi 90
Tianjin 78
Buffalo 68
Hangzhou 68
Ann Arbor 67
Milan 53
Shanghai 47
Moscow 45
Pavia 44
Munich 38
Council Bluffs 37
Toronto 36
Redondo Beach 33
Woodbridge 30
São Paulo 29
Tokyo 27
Santa Clara 26
Turku 26
Norwalk 25
Johannesburg 23
Da Nang 21
Warsaw 21
Chennai 20
San Francisco 20
The Dalles 20
Orem 19
Frankfurt am Main 18
Guangzhou 18
Falls Church 17
Brooklyn 16
Brussels 16
Haiphong 16
Seattle 16
Verona 16
London 15
Poplar 15
Belo Horizonte 14
Kunming 14
Washington 14
Des Moines 13
Jinan 13
Boston 12
Nairobi 12
Rome 12
Stockholm 12
Zhengzhou 12
Denver 11
Hải Dương 11
Mexico City 11
Chicago 10
Dearborn 10
Fairfield 10
Houston 10
Montreal 10
Nuremberg 10
Tashkent 10
Atlanta 9
Dhaka 9
Taizhou 9
Vienna 9
Ankara 8
Baghdad 8
Brasília 8
Ningbo 8
Baku 7
Columbus 7
Falkenstein 7
Fuzhou 7
Istanbul 7
Rio de Janeiro 7
Amman 6
Clifton 6
Guarulhos 6
Lanzhou 6
Phoenix 6
Totale 7.939
Salva come PNG Salva come JPEG
Nome #
Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation. 166
Alterata espressione dei canali del Ca2+ in cellule progenitrici endoteliali di pazienti affetti da carcinoma cellulare renale, mielofibrosi idiopatica e tumore della mammella 158
ANALYSIS OF THE MITOCHONDRIAL FERRITIN PHYSIOPATHOLOGICAL ROLE IN SIDEROBLASTIC ERYTHROPOIESIS 150
A rule-based expert system for automatic implementation of somatic variant clinical interpretation guidelines 150
Chronic lymphocytic leukemia with 6q- shows distinct hematological features and intermediate prognosis. 143
A WHO classification-based prognostic scoring system (WPSS) for predicting survival in myelodysplastic syndromes 143
Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndrome 142
A prognostic model for predicting the impact of comorbidities on survival of patients with myelodysplastic syndromes 141
Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts 136
27P * Common gene signature expressed by breast and kidney cancers-derived endothelial colony forming cells 135
Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders 130
An unusual clinical presentation of multiple myeloma with involvement of the oro-pharynx. 130
Circulating endothelial cell separation from peripheral blood of patients affected by myelodysplastic syndromes: Preliminary results obtained by a new immunomagnetic procedure 130
Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes. 129
Classification and prognostic evaluation of myelodysplastic syndromes 126
Burkitt-like lymphoma infiltrating a hyperfunctioning thyroid adenoma and presenting as a hot nodule. 121
CD34 and CD2 expression in acute promyelocytic leukemia. 120
Complex Patterns of Chromosome 11 Aberrations in Myeloid Malignancies Target CBL, MLL, DDB1 and LMO2. 117
WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). 115
Ultrastructural and functional differences between normal and tumor endothelial progenitor cells 114
Over-expression of mitochondrial ferritin affects the JAK2/STAT5 pathway in K562 cells and causes mitochondrial iron accumulation. 113
CHARACTERIZATION OF A CELLULAR MODEL FOR THE STUDY OF MITOCHONDRIAL FERRITIN PHYSIOPATHOLOGICAL ROLE IN SIDEROBLASTIC ERYTHROPOIESIS 113
Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype. 111
Clinical and biological implications of driver mutations in myelodysplastic syndromes 111
Dendritic cells and vascular endothelial growth factor in colorectal cancer: correlations with clinicobiological findings. 110
Consolidation treatment with autologous peripheral blood progenitor cell transplantation in acute myeloid leukemia: a single center experience. 110
CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure. 108
Clinical evaluation of extra-hematological comorbidity in myelodysplastic syndromes: "ready-to-wear" versus "made-to-measure" tools. 108
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation 107
Should cytoreductive treatment be performed before transplantation in patients with high-risk myelodysplastic syndrome? 106
Prognosis of secondary acute myeloid leukemia 106
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms 106
Consolidation treatment with autologous peripheral blood progenitor cell transplantation in acute myeloid leukemia 105
Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study. 104
Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia 103
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes 103
Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. 102
Morphological features and prognostic implication in a retrospective analysis of 370 patients with myelodysplastic syndrome 101
VASCULAR ENDOTHELIAL GROWTH FACTOR OVEREXPRESSION IN BONE MARROW CELLS FROM PATIENTS WITH MYELODYSPLASTIC SYNDROME: BIOLOGICAL AND CLINICAL RELEVANCE 100
Dendritic cell recovery after allogeneic stem-cell transplantation in acute leukemia: correlations with clinical and transplant characteristics. 100
Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. 100
Gene expression profiling of CD34+ cells in patients with the 5q- syndrome 99
Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment 99
PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia 99
Effects of mitochondrial ferritin overexpression in normal and sideroblastic erythroid progenitors. 99
Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome 98
Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes 97
Role of the molecular staging and response in the management of follicular lymphoma patients 97
Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. 94
Flow cytometry immunophenotyping for the evaluation of bone marrow dysplasia. 94
Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes-proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS. 94
Treatment of anemia with erythroid stimulating agents in myelodysplastic syndromes. 94
SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts 94
Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes 93
Predicting survival and leukemic evolution in patients with myelodysplastic syndrome 92
In patients with myelodysplastic syndromes response to rHuEPO and G-CSF treatment is related to an increase of cytogenetically normal CD34 cells. 91
Prevalence, incidence and types of mild anemia in the elderly: the "Health and Anemia" population-based study. 91
Remodelling of the Ca2+ signalling machinery in endothelial progenitor cells isolated from breast cancer patients 91
Hematologic responses with deferasirox therapy in transfusion-dependent myelodysplastic syndromes patients. 90
Pretransplantation therapy with hypomethylating agents in patients with myelodysplastic syndromes receiving reduced-intensity conditioning regimens. 90
JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders 90
Haploinsufficiency of RPS14 in 5q− syndrome is associated with deregulation of ribosomal- and translation-related genes 89
Myelodysplastic syndromes and bone marrow microenvironment. 89
Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. 89
Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. 89
THE IMPACT OF THE DEGREE OF ANEMIA ON SURVIVAL OF PATIENTS WITH MYELODYSPLASTIC SYNDROME. A BASIS FOR PROGNOSTIC ASSESSMENT AND CLINICAL DECISION MAKING 88
Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. 87
Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes. 87
Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1 87
Methylenetetrahydrofolate reductase C677T and A1298C gene variants in adult non-Hodgkin's lymphoma patients: association with toxicity and survival 87
Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. 86
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study 85
Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival. 85
Improving the prognostic assessment of myelodysplastic syndromes by understanding the biology of the disease 85
Simian virus 40 and lymphoproliferative disorder. 84
Splenectomy for treatment of immune thrombocytopenic purpura. 84
Dendritic cells in acute promyelocytic leukaemia. 84
Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM) 84
The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts. 84
A Randomized Double-Blind Placebo-Controlled Clinical Study to Evaluate the Effect on the Weight of a Medical Device with Polyglucosamine L112 in a Group of Overweight and Obese Subjects 83
Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group 83
Lymphocyte subpopulation and dendritic cell phenotyping during antineoplastic therapy in human solid tumors. 82
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet 82
Soluble urokinase-type plasminogen activator receptor (suPAR) as an independent factor predicting worse prognosis and extra-bone marrow involvement in multiple myeloma patients. 81
Myelodysplastic syndromes with bone marrow fibrosis. 81
DHFR 19-bp insertion/deletion polymorphism and MTHFR C677T in adult acute lymphoblastic leukaemia: is the risk reduction due to intracellular folate unbalancing? 81
Multilineage involvement in the 5q- syndrome: a fluorescent in situ hybridization study on bone marrow smears. 80
rHuEpo administration in patients with low-risk myelodysplastic syndromes: evaluation of erythroid precursors' response by fluorescence in situ hybridization on May-Grunwald-Giemsa-stained bone marrow samples. 80
Flow cytometric analysis of peripheral blood dendritic cells in patients with severe sepsis. 80
Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia 80
Risk factors for Gram-negative infections in neutropenic patients. 80
From cancer patients to cancer survivors: the issue of Cardioncology--a biological perspective. 80
Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes 80
Flow cytometric detection of accelerated telomere shortening in myelodysplastic syndromes: correlations with aetiological and clinical-biological findings. 79
Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. 79
The genetic basis of myelodysplasia and its clinical relevance 78
Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. 77
High resolution melting for the identification of mutations in the iron responsive element of the ferritin light chain gene. 77
Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome 77
Outcome after allogeneic bone marrow transplantation in cytogenetic high-risk myelodysplastic syndromes and acute myeloid leukemia. 77
Totale 10.039
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.506
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 52.506
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202117 0 0 0 0 0 0 0 0 0 0 0 17
2021/2022651 9 0 21 12 36 20 10 30 39 28 85 361
2022/20231.815 178 102 19 194 201 192 2 129 727 13 34 24
2023/2024665 56 182 28 63 53 175 11 24 3 15 21 34
2024/20251.612 61 145 86 39 28 64 47 138 325 60 183 436
2025/20264.028 251 295 424 521 400 150 900 191 343 307 173 73
Totale 12.234